CPAP;Heliox Effects on Stability and Therapeutics - C.H.E.S.T.
Phase 1
- Conditions
- Respiratory Distress requiring CPAPExamples: Bronchilitis, post-exturbation, Upper Airway Obstruction...
- Registration Number
- EUCTR2005-002585-11-GB
- Lead Sponsor
- Imperial College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Age less/equal then 1 year(chronological age), respiratory distress requiring CPAP
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Pneumothorax, extreme respiratory failure,imminent intubation,haemodynamically unstable, FiO2>0.6
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: work of breathing;Secondary Objective: Oxygenation<br>Carbon Dioxide clearance;Primary end point(s): Work of breathing
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie CPAP and Heliox therapy in respiratory distress management?
How does CPAP with Heliox compare to standard oxygen therapy in treating upper airway obstruction?
Are there specific biomarkers that predict response to CPAP and Heliox in bronchilitis patients?
What adverse events are associated with CPAP and Heliox treatment in post-extubation respiratory failure?
What combination therapies or alternative approaches are being explored alongside CPAP for respiratory distress?